Physician

Leonardo Forero, MD

According to 2025 Medicare claims, Leonardo Forero, MD (NPI: 1700847464) practices medical oncology in the Amarillo, TX market, with the plurality of this provider's patient population coming from Potter, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 79124-2167. Forero is affiliated with the Texoma Clinical Partners ACO, LLC (ACO ID: A4585) and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Forero's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 634 traditional Medicare patients, billed 228,411 HCPCS/CPT codes, and received $2,942,522 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 309 prescription claims across 62 beneficiaries totaling $576,353 in drug costs, led by Xtandi (Enzalutamide). DME data shows 40 claims. Open Payments data shows 14 records totaling $51,884. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,785,400 and ending at $2,942,522. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $676,594 and ending at $576,353. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $10,797 to $1,178.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	300	165,402	$1,785,400
2016	531	170,575	$2,005,994
2017	716	208,281	$2,713,788
2018	672	201,646	$1,945,458
2019	710	279,065	$3,142,177
2020	739	329,157	$3,720,704
2021	831	421,890	$4,634,939
2022	791	299,347	$3,445,786
2023	726	269,120	$2,940,069
2024	634	228,411	$2,942,522

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	75	536	$676,594
2016	64	441	$488,419
2017	59	405	$628,610
2018	64	350	$850,206
2019	61	334	$625,637
2020	64	423	$757,649
2021	83	551	$1,207,599
2022	79	401	$1,121,212
2023	67	319	$701,687
2024	62	309	$576,353

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	246	$75,257
2016	N/R	36	$875
2017	N/R	50	$21,101
2018	N/R	29	$7,304
2019	N/R	15	$843
2020	N/R	54	$6,872
2021	N/R	55	$5,012
2022	N/R	80	$3,106
2023	N/R	N/R	N/R
2024	N/R	40	$1,823

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	137	210	$62
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	166	326	$46
96372	Injection of drug or substance under skin or into muscle	127	272	$10
36415	Insertion of needle into vein for collection of blood sample	169	377	$9
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	118	14,150	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	21	630	$281,635
Erivedge	Vismodegib	18	504	$166,573
Tagrisso	Osimertinib Mesylate	11	330	$85,552
Abiraterone Acetate	Abiraterone Acetate	12	360	$1,563
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	44	746	$1,136

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	13	$946
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$681
E0431	Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing	Y	N/R	12	$197

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$638	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	7	$51,246	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Leonardo Forero, MD?

Tedicare shows public-source Medicare data for Leonardo Forero, MD (NPI 1700847464), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Leonardo Forero, MD have ACO affiliation data?

Leonardo Forero, MD is shown with ACO affiliation data for Texoma Clinical Partners ACO, LLC (MSSP, ACO ID A4585) and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Leonardo Forero, MD?

Leonardo Forero, MD is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Leonardo Forero, MD have Open Payments data?

Leonardo Forero, MD has 14 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.